Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efinopegdutide in precirrhotic NASH
NCT05877547Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 26
01
Overview
A Phase 2 trial of efinopegdutide in Nonalcoholic steatohepatitis (NASH), sponsored by Merck & Co.. Started Jun 2023; status: completed.
02
Drugs
efinopegdutide
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05877547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877547.